Related Party

6 Months Ended

Jun. 30, 2012

Related Party

2. Related Party

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending June 30, 2012 and 2011, MD Anderson related party research and development expense was $367,588 and $25,000, respectively. MD Anderson related party research and development expense for the quarter ending June 30, 2012 consisted of $345,000 for technology impairment expense and $22,588 for siRNA patent expense. As of June 30, 2012, the Company had accrued expense of $52,700 for clinical trial expense for the related party and $50,000 in accrued license payments payable due to the related party for past patent expenses for the Company’s Technology License. See Notes 5 and 6. For the quarter ended June 30, 2011, the Company had $25,000 in R&D related party expense for clinical trial hospital expense.